Specimens were obtained from patients with appropriate consent from institutional review boards. Using a co-isolation protocol, DNA and RNA were purified. In total, 800 patients were assayed on at least one platform. Different numbers of patients were used for each platform using the largest number of patients available at time of data freeze; 466 samples (463 patients) were in common across 5/6 platforms (excluding RPPA) and 348 patients were in common on 6/6 platforms. Technology platforms used include: 1) gene expression DNA microarrays51 (link), 2) DNA methylation arrays, 3) microRNA sequencing, 4) Affymetrix SNP arrays, 5) exome sequencing, and 6) Reverse Phase Protein Arrays. Each platform, except for the exome sequencing, was used in a de novo subtype discovery analysis (Supplemental Methods ) which were included in a single analysis to define an overall subtype architecture. Additional integrated across platform computational analyses were preformed including PARADIGM32 (link) and MEMo40 (link).
All of the primary sequence files are deposited in CGHub (https://cghub.ucsc.edu/ ); all other data including mutation annotation file are deposited at the Data Coordinating Center (DCC) (http://cancergenome.nih.gov/ ). Sample lists, data matrices and supporting data can be found at (http://tcga-data.nci.nih.gov/docs/publications/brca_2012/ ). The data can be explored via the ISB Regulome Explorer (http://explorer.cancerregulome.org/ ) and the cBio Cancer Genomics Portal (http://cbioportal.org ). Data descriptions can be found at (https://wiki.nci.nih.gov/display/TCGA/TCGA+Data+Primer ) and in Supplementary Methods . Reprints and permissions information is available at www.nature.com/reprints .
All of the primary sequence files are deposited in CGHub (